In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2525-2532

  Canducci, Filippo ^a,b   Ceresola, Elisa Rita ^c   Saita, Diego ^c   Castagna, Antonella ^b   Gianotti, Nicola ^b   Underwood, Mark ^d   Burioni, Roberto ^b,c   Lazzarin, Adriano ^b,c   Clementi, Massimo ^b,c  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Cross resistance; HIV eradication; HIV reservoir; HIV therapy; Viral fitness

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL TYPE; CLONAL VARIATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LYMPHOCYTE; MACROPHAGE; MOLECULAR CLONING; MONOCYTE; MUTANT; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENETICS; VIRUS RECOMBINANT;

CROSS-RESISTANCE; HIV ERADICATION; HIV RESERVOIR; HIV THERAPY; VIRAL FITNESS;

ANTI-HIV AGENTS; CELLS, CULTURED; CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; LYMPHOCYTES; MACROPHAGES; PYRROLIDINONES; QUINOLONES; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 84886247956     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt220     Document Type: Article

References (23)

1. Canducci F, Sampaolo M, Marinozzi MC et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. Aids 2009; 23: 455-60.
2. Canducci F, Marinozzi MC, Sampaolo M et al. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 2010; 65: 425-33.
3. Canducci F, Barda B, Ceresola E et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect 2011; 17; 928-34.
4. Cossarini F, Castagna A, Lazzarin A. Raltegravir in treatment naive patients. Eur J Med Res 2009; 14: 22-9.
5. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48: 931-9.
6. Mesplede T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIVAIDS 2012; 7: 401-8.
7. Canducci F, Ceresola ER, Boeri E et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011; 204: 1811-5.
8. Cossarini F, Boeri E, Canducci F et al. Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. J Acquir Immune Defic Syndr 2011; 56: e51-4.
9. Sigal A, Kim JT, Balazs AB et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-8.
10. Aquaro S, Perno CF, Balestra E et al. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 1997; 62: 138-43.
11. Aquaro S, Perno CF. Assessing the relative efficacy of antiretroviral activity of different drugs on macrophages. Methods Mol Biol 2005; 304: 445-53.
12. Scopelliti F, Pollicita M, Ceccherini-Silberstein F et al. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res 2011; 92: 255-61.
13. Marsden MD, Avancena P, Kitchen CM et al. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother 2011; 55: 3696-702.
14. Canducci F, Marinozzi MC, Sampaolo M et al. Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology 2009; 6: 4.
15. Boeri E, Canducci F, Grasso MA et al. Phylogenetic internal control for HIV-1 genotypic antiretroviral testing. New Microbiol 2004; 27: 105-9.
16. Boeri E, Gianotti N, Canducci F et al. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. AIDS Res Hum Retroviruses 2003; 19: 1151-3.
17. Metifiot M, Vandegraaff N, Maddali K et al. Elvitegravir overcomes resistance to raltegravir induced by integrasemutation Y143. AIDS 2011; 25: 1175-8.18
18. Murray JM, Emery S, Kelleher AD et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21: 2315-21.
19. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012; 16: 279-90.
20. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother 2009; 20: 63-78.
21. Hightower KE, Wang R, Deanda F et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravirfrom wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55, 4552-9.
22. Kobayashi M, Yoshinaga T, Seki Tet al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
23. Garrido C, Villacian J, Zahonero N et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012; 56: 2873-8